Table 2.

Clinical trials with antiCD137, antiOX40, antiCD27, and antiGITR mAb

Study agent (ClinicalTrial.Gov identifier)Indication diseaseStatus (Oct 2012)DosesPhase
Anti-CD137BMS-663513 (NCT00309023)Metastatic solid tumorsTerminatedBMS-663513 (0.3, 1, 3, 6, 10, 15 mg/kg)I/II
BMS-663513 (NCT00351325)Metastatic solid tumorsTerminatedBMS-663513 (0.3, 1, 3, 10 mg/kg) every 3 or 6 wkI
BMS-663513 (NCT00461110)Metastatic Non–small cell lung cancerTerminatedBMS-663513 (0.3, 1, 3, 6, 10 mg/kg)I
BMS-663513 (NCT00612664)Unresectable stage III or IV Malignant MelanomaCompletedBMS-663513 (0.1,1,5 mg/kg)II
BMS-663513 plus Ipilimumab (NCT00803374)Unresectable stage III or IV Malignant MelanomaWithdrawnBMS-663513 (0.1, 0.3, 1, 3, 10 mg/kg)I
Ipilimumab (10 mg/kg)
PFZ-05082566 plus rituximab (NCT01307267)Series A. Solid tumorRecruitingA. PFZ-05082566 Dose escalationI
B. Rituximab 375 mg/m2
Series B. Non-Hodgkin's lymphomaPFZ-05082566 Dose escalation
BMS-663513 (NCT01471210)Metastatic solid tumorsRecruitingBMS-663513 (0.03,0.1,0.3 mg/kg)I
Anti-OX40Anti-OX40 plus cyclophosphamide (NCT01303705)Metastatic prostate CancerRecruitingAnti-OX40 (0.4 mg/kg)I/II
Cyclophosphamide (300, 600, and 900 mg/m2)
Anti-OX40 plus radiation (NCT01642290)Metastatic breast CancerRecruitingAnti-OX40 (0.4 mg/kg)I
Anti-OX40 plus KLH and Tetanus toxoid vaccine (NCT01644968)Metastatic solid tumorsActive, not recruitingAnti-OX40 (0.1, 0.4, 2 mg/kg d1, 3, 5)I
Anti-CD27CDX-1127 (NCT01460134)Hematologic malignancies metastatic solid tumorsRecruitingCDX-1127 (0.1–10 mg/kg)I
Anti-GITRTRX518 (NCT01239134)Unresectable stage III or IV Malignant MelanomaRecruitingDose escalationI